Zhao Jie-min, Wu Ai-zhen, Shi Liang-rong
Department of Oncology, the First People's Hospital of Changzhou, Jiangsu.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007 Aug;27(8):736-8.
To investigate the effects of Shenqi Fuzheng injection (SQFZI) combined with docetaxcl, flurouracil and calcium folinate in treating advanced gastric carcinoma, and to evaluate the action of SQFZI for enhancing therapeutic effect and alleviating adverse reaction of chemotherapy.
Sixty advanced gastric cancer patients were assigned to two groups randomly, the control group treated with chemotherapy alone and the treated group treated with SQFZI combined chemotherapy. Chemotherapy regimens (TFC) was given to all patients consisting of docetaxel 75 mg/m2 intravenous dripping on the 1st day, flurouracil (5-FU) 350 mg/m2 and calcium folinate (CF) 120 mg/m2 intravenous dripping with micro-pump continuously from day 1 to 5, for 21-28 days as a cycle. To patients in the treated group, starting from 3 days before chemotherapy, SQFZI 250 mL was dripped every day for 14 successive days. The clinic effects were evaluated after two-cycle treatment.
The short-term effective rate was 40.0% in the treated group and 33.3% in the control group. As compared with those in the control group, patients in the treated group after treatment had a higher Karnofsky score (chi2 = 7.21, P < 0.05) and body weight (chi2 = 11.47, P < 0.05), lesser adverse reactions in decreasing of peripheral blood leucocyte, damage of peripheral nerve, adverse reaction of gastrointestinal tract, as well as better immune function.
SQFZI could effectively improve the clinical symptoms induced by chemotherapy regimen TFC, alleviate the adverse reaction, raise patients' quality of life and their immune function.
探讨参芪扶正注射液(SQFZI)联合多西他赛、氟尿嘧啶及亚叶酸钙治疗晚期胃癌的疗效,评价SQFZI在增强化疗疗效及减轻化疗不良反应方面的作用。
将60例晚期胃癌患者随机分为两组,对照组单纯化疗,治疗组采用SQFZI联合化疗。所有患者均采用化疗方案(TFC),即多西他赛75mg/m²于第1天静脉滴注,氟尿嘧啶(5-FU)350mg/m²及亚叶酸钙(CF)120mg/m²自第1天至第5天用微量泵持续静脉滴注,21-28天为1个周期。治疗组患者从化疗前3天开始,每天静脉滴注SQFZI 250mL,连续14天。两个周期治疗后评价临床疗效。
治疗组近期有效率为40.0%,对照组为33.3%。与对照组相比,治疗组治疗后患者卡氏评分(χ² = 7.21,P < 0.05)及体重(χ² = 11.47,P < 0.05)更高,外周血白细胞减少、外周神经损伤、胃肠道不良反应等不良反应更少,免疫功能更好。
SQFZI可有效改善化疗方案TFC所致临床症状,减轻不良反应,提高患者生活质量及免疫功能。